Nxera seeks schizophrenia programme buyer after Boehringer snub
Japan-based Nxera Pharma is seeking buyers for its Phase II-ready schizophrenia programme after Boehringer Ingelheim decided not to exercise a…
Central Nervous System
-
-
Sanofi shares fall 6% after double setback for MS drug tolebrutinib
Sanofi’s experimental drug for multiple sclerosis (MS) has been hit with another US regulatory delay, a setback compounded by disappointing…
-
Aspen closes $115m in Series C to advance Parkinson’s cell therapy
US-based Aspen Neuroscience has closed a Series C funding round, raising $115m to further the clinical development of its lead…
-
Pfizer and Tris reach settlement with Texas over ADHD drug allegations
Pfizer and Tris Pharma have agreed to pay $41.5m to settle allegations by Texas Attorney General Ken Paxton that they…
-
High-dose Spinraza inches closer to EU approval despite FDA setback
A high-dose version of Biogen’s Spinraza (nusinersen) could soon be available in Europe, after a panel recommended the formulation’s approval.…
-
Modulight secures $12m to shine precise light on neurological diseases
Modulight Biotherapeutics has raised $12.2m in seed financing to advance its optogenetic technology being developed for neurological disorders. The seed…
-
J&J’s Caplyta wins MDD approval to extend revenue horizon
Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J&J) saw in…
-
Lundbeck and Contera partner for oligonucleotide-based medicines
H Lundbeck and Contera Pharma have announced a research partnership aimed at expediting the discovery as well as development of…
-
Oragenics partners Receptor.AI for brain health candidate portfolio
Clinical-stage biotechnology company Oragenics has announced a strategic collaboration with the US-based tech bio firm Receptor.AI to expedite the development…
-
FDA lifts clinical hold on Neurizon’s ALS drug
The US Food and Drug Administration (FDA) has released its clinical hold on Neurizon Therapeutics’ NUZ‑001, paving the way for…
